A Phase 2, Open-label, Single-arm Study Of 18f-sodium Fluoride Pet/ct Bone Imaging In Enzalutamide-treated Chemotherapy-naïve Patients With Bone-metastatic Castration-resistant Prostate Cancer

Trial Profile

A Phase 2, Open-label, Single-arm Study Of 18f-sodium Fluoride Pet/ct Bone Imaging In Enzalutamide-treated Chemotherapy-naïve Patients With Bone-metastatic Castration-resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 07 Aug 2017 Planned End Date changed from 1 Jul 2019 to 14 Mar 2019.
    • 07 Aug 2017 Planned primary completion date changed from 1 Jul 2019 to 14 Dec 2018.
    • 17 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top